全文获取类型
收费全文 | 140177篇 |
免费 | 45579篇 |
国内免费 | 879篇 |
专业分类
耳鼻咽喉 | 1978篇 |
儿科学 | 5655篇 |
妇产科学 | 1093篇 |
基础医学 | 26908篇 |
口腔科学 | 7333篇 |
临床医学 | 16568篇 |
内科学 | 28514篇 |
皮肤病学 | 4710篇 |
神经病学 | 19523篇 |
特种医学 | 6787篇 |
外国民族医学 | 16篇 |
外科学 | 22567篇 |
综合类 | 4755篇 |
现状与发展 | 4篇 |
一般理论 | 8篇 |
预防医学 | 8980篇 |
眼科学 | 1655篇 |
药学 | 11689篇 |
21篇 | |
中国医学 | 2449篇 |
肿瘤学 | 15422篇 |
出版年
2024年 | 87篇 |
2023年 | 450篇 |
2022年 | 826篇 |
2021年 | 2695篇 |
2020年 | 7043篇 |
2019年 | 12253篇 |
2018年 | 11837篇 |
2017年 | 13122篇 |
2016年 | 12274篇 |
2015年 | 12241篇 |
2014年 | 12954篇 |
2013年 | 13159篇 |
2012年 | 11830篇 |
2011年 | 12032篇 |
2010年 | 10416篇 |
2009年 | 6777篇 |
2008年 | 7270篇 |
2007年 | 5587篇 |
2006年 | 5438篇 |
2005年 | 5072篇 |
2004年 | 4810篇 |
2003年 | 4408篇 |
2002年 | 4036篇 |
2001年 | 3164篇 |
2000年 | 1898篇 |
1999年 | 658篇 |
1998年 | 411篇 |
1997年 | 360篇 |
1996年 | 308篇 |
1995年 | 258篇 |
1994年 | 285篇 |
1993年 | 202篇 |
1992年 | 203篇 |
1991年 | 184篇 |
1990年 | 173篇 |
1989年 | 159篇 |
1988年 | 136篇 |
1987年 | 135篇 |
1986年 | 109篇 |
1985年 | 157篇 |
1984年 | 172篇 |
1983年 | 122篇 |
1982年 | 141篇 |
1981年 | 109篇 |
1980年 | 131篇 |
1979年 | 103篇 |
1978年 | 97篇 |
1977年 | 77篇 |
1976年 | 86篇 |
1973年 | 61篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的 临床观察白花蛇舌草干预湿热瘀滞型肠内多发息肉患者内镜治疗术后复发情况。方法 采用前瞻性的随机空白对照试验设计,选取2019年9月1日—2020年12月31日上海中医药大学附属普陀医院消化科收治的门诊及住院结直肠多发息肉患者132例作为研究对象。采用随机方法分为对照组和试验组,每组66例。对照组行内镜治疗术给予常规治疗后无药物干预,试验组在对照基础上给予白花蛇舌草汤剂(每日取白花蛇舌草15 g、大枣3枚,煎取400 mL汤剂,分2次饭后温服)治疗,连续干预1年。观察并比较两组术前与术后1年肠道内息肉的复发率、息肉数目、息肉最大直径、中医证候评分及肝肾功能及血常规的差异。结果 干预1年后,试验组复发9例(14.75%),对照组复发21例(33.33%),两组息肉复发率比较,差异有统计学意义(P<0.05)。试验组腺瘤、伴重度异型增生、体质量指数(BMI)≥24 kg·m-2患者治疗后息肉复发率均较对照组同类型降低,差异显著(P<0.05);术后1年试验组息肉最大直径及息肉数目均较对照组显著减小,差异显著(P<0.05);术后1年试验组中医证候各项评分均显著低于对照组(P<0.05);术后1年,两组中医证候疗效比较,差异具有统计学意义(P<0.05),且术前、术后1年两组患者肝肾功能、凝血功能等安全性指标无显著差异。结论 应用白花蛇舌草干预结直肠息肉术后患者,1年后明显降低肠内息肉的复发率,尤以腺瘤性息肉、重度异型增生、BMI超重患者更显著,不仅改善临床症状,还能有效预防结直肠息肉的复发,改善患者的预后。 相似文献
2.
《Diagnostic Histopathology》2022,28(3):156-160
Breast core biopsies are a standard component of the triple approach that includes clinical examination, imaging and tissue sampling. Conventional cores, diagnostic vacuum assisted biopsy and vacuum assisted excisions are established methods for sampling and managing breast lesions. It is important to be aware of the potential pitfalls in the technical handling and interpretation of the limited core biopsy samples. Here, we present a clinically oriented, well illustrated overview of the common diagnostic pitfalls based on the author's diagnostic and second opinion practice, emphasize the value of clinicopathological correlation and provide histological tips and clues with useful immunohistochemistry to aid the reporting pathologists in their daily interpretation of breast core biopsies. 相似文献
3.
4.
5.
6.
Phoebe Hammer Kevin White Stephanie Mengden Vessy Korcheva Philipp W. Raess 《Journal of cutaneous pathology》2019,46(5):343-346
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances. 相似文献
7.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
8.
9.
10.
Daniel Schar Pawin Padungtod Nguyen Tung Michael OLeary Wantanee Kalpravidh Filip Claes 《Influenza and other respiratory viruses》2019,13(6):618-621
Among the chief limitations in achieving early detection and control of animal‐origin influenza of pandemic potential in high‐risk livestock populations is the existing lag time between sample collection and diagnostic result. Advances in molecular diagnostics are permitting deployment of affordable, rapid, highly sensitive, and specific point‐of‐capture assays, providing opportunities for targeted surveillance driving containment strategies with potentially compelling returns on investment. Interrupting disease transmission at source holds promise of disrupting cycles of animal‐origin influenza incursion to endemicity and limiting impact on animal production, food security, and public health. Adoption of new point‐of‐capture diagnostics should be undertaken in the context of promoting robust veterinary services systems and parallel support for operationalizing pre‐authorized plans and communication strategies that will ensure that the full potential of these new platforms is realized. 相似文献